Drug Delivery Technologies: Players, Products & Prospects to 2018 : Market Research Report

Drug Delivery Technologies: Players, Products & Prospects to 2018

Published by: Espicom Healthcare Intelligence

Published: Jun. 26, 2009 - 472 Pages

Report Overview: Controlled-Release Delivery Technologies; Nano-enabled Delivery Technologies; Nucleic Acid Delivery Technologies; Targeted Delivery Technologies; Competitor Ratio Analysis Summary
Drug Delivery Technologies: Controlled-Release
EXECUTIVE SUMMARY
INTRODUCTION: Overview of controlled-release delivery: past, present & future; Leading controlled-release technology platforms & characteristics; Controlled delivery profiles; Drug release profiles; Controlled-release delivery: motivators & resistors; Motivators; Controlled-Release technology motivators; Resistors; Controlled-Release technology resistors; Controlled-release delivery: impact on product lifecycles; Impact of reformulation on product life-cycle
CONTROLE D-RELEASE DELIVERY: Types of controlled-release delivery used by pharma industry; Activated controlled-release delivery; Activated controlled-release delivery - ALZA’s OROS systems; Degradation controlled-release delivery; Degradation controlled-release delivery - SkyePharma’s GEOMATRIX; Diffusion controlled-release delivery; Monolithic diffusion controlled-release delivery - LaboPharm’s Contramid; Reservoir diffusion controlled-release delivery - Impax’ CMDS; Combined controlled-release delivery - Flamel’s Micropump; Advantages and disadvantages of controlled-release platforms; Current therapeutic application of controlled-release in drug delivery; Leading brands that utilise controlled-release delivery; Leading controlled-release approved drugs; Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES: Leading controlled-release drug delivery companies; Leading controlled-release drug delivery companies; Partnerships & acquisitions; Strategic developmental & commercialisation partnerships; Merger & acquisitions; Recent partnerships & acquisitions in the controlled-release field; Intellectual Property; Controlled-Release patents
THE controlLed-release MARKET: Now 2009; Approved controlled-release product sales; Future 2018; Global controlled-release product sales; Novel controlled-release product sales
COMPETITOR ANALYSIS: Movers & Shakers: Cutting edge or losing their grip; Movers & shakers in controlled-release drug delivery systems
COMPANY PROFILES: AlphaRx Corporation (www.alpharx.com); ALZA Corporation (www.alza.com); Antares Pharma, Inc. (www.antarespharma.com); Biovail Corporation (www.Biovail.com); Camurus AB (www.camurus.se); Cipher Pharmaceuticals, Inc. (www.cipherpharma.com); Debiopharm Group (www.debio.com); DelSite Biotechnologies, Inc. (www.delsite.com); Depomed, Inc. (www.depomedinc.com); Durect Corporation (www.Durect.com); Elan Corporation (www.elan.com); Elite Pharmaceuticals, Inc. (www.elitepharma.com); Endo Pharmaceuticals, Inc. (www.endo.com); Ethypharm SA (www.ethypharm.com); Eurand (www.eurand.com); Flamel Technologies, Inc. (www.flamel.com); Glycologic, Ltd (www.glycologic.co.uk); KV Pharmaceuticals, Inc (www.kvpharmaceutical.com); Labopharm, Inc. (www.labopharm.com); Lavipharm SA (www.lavipharm.com); Nano Interface Technology (www.nanointerfacetech.com); OctoPlus N.V. (www.octoplus.nl); Penwest Pharmaceuticals (www.penw.com); SCOL R Pharma, Inc. (www.scolr.com); Shire, Plc (www.shire.com); Skinvisible, Inc. (www.skinvisible.com); SkyePharma (www.skyepharma.com); Spherics (www.spherics.com); Watson Pharmaceuticals (www.watson.com)
APPENDIX 1: Global controlled-release approved drugs sales 2008-2018 (US$million)
APPENDIX 2: Global controlled-release developmental drugs sales 2008-2018 (US$million)
APPENDIX 3: Competitor Ratio Analysis Criteria; Key Controlled-release delivery companies by 2015
BIBLIOGRAPHY
GLOSSARY
Acronyms
Endnotes
Drug Delivery Technologies: Nan otechnology
EXECUTIVE SUMMARY
INTRODUCTION: Overview of nanotechnology: past, present & future; Multifunctional nanotechnology platform; Nanotechnology: motivators & resistors; Motivators; Nanotechnology motivators; Resistors; Nanotechnology resistors; Nanomedicines, formulations and product regeneration; Failure rates at each stage of clinical drug development
NANOTECHNOLOGY IN DRUG DELIVERY: Core nanotechnology used by the pharma industry; Nano-engineered drugs; Nano-carriers; Dendrimer structure; Liposome structure; Micelle structure; Polymeric nanoparticle structure - Abraxane; Current therapeutic applications of nanotechnology in drug delivery; Leading brands that utilise nanotechnology delivery; Nanotechnology-enabled approved drugs; Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES: Leading nanotechnology drug delivery companies; Leading nanotechnology-enabled drug delivery companies; Partnerships & acquisitions; Strategic development & commercialisation partnerships and joint ventures; Mergers, acquisitions, start ups & spin offs; Recent partnerships & acquisitions in the nanotechnology field; Intellectual Property; Nanotechnology patents
THE NANOTECHNOLOGY MARKET: Now 2009; Leading approved nano-enabled product sales; Leading companies developing nano-enabled product sales; Future 2018; Novel nano-enabled product sales; Global nano-enabled product sales
COMPETITOR ANALYSIS: Movers & Shakers: Cutting edge or losing their grip; Movers & shakers in nanotechnology drug delivery systems
COMPANY PROFILES: Access Pharmaceuticals (www.accesspharma.com); AlphaRx Corporation (www.alpharx.com); ALZA Corporation (www.alza.com); Aphios Corporation (www.aphios.com); APR Applied Pharma Research (www.apr.com); BioSante Pharmaceuticals (www.biosantepharma.com); Calando Pharmaceuticals (www. calandopharma.com); Camurus AB (www.camurus.se); Cerulean Pharma Inc (www.ceruleanrx.com); CytImmune Sciences Inc (www.cytimmune.com); Elan Corporation (www.elan.com); Enzon Pharmaceuticals, Inc. (www.enzon.com); Gilead Sciences (www.gilead.com); Introgen Therapeutics (www.introgen.com); Mersana Therapeutics (www.mersana.com); Nano Interface Technology (www.nanointerfacetech.com); Nanos Biotechnology GmbH (www.nano-s.com); NanoBio Corporation (www.nanobio.com); NanoBioMagnetics (www.nanobmi.com); Nanobiotix (www.nanobiotix.com); NanoCarrier (www.nanocarrier.co.jp); Nanotechnology Victoria, Ltd (www.nanovic.com); NanoMaterials Technology (www.nanomt.com); Nanotherapeutics (www.nanotherapeutics.com); Novavax (www.novavax.com); SkyePharma (www.skyepharma.com); Spherics (www.spherics.com); Starpharma (www.starpharma.com)
APPENDIX 1: Global nanotechnology approved drugs sales 2008-2018
APPENDIX 2: Global nanotechnology developmental drugs sales 2008-2018
APPENDIX 3: Competitor Ratio Analysis Criteria; Key nanotechnology delivery companies by 2018
GLOSSARY
ACRONYMS
Bibliography
Endnotes: Drug Delivery Technologies: Nucleic Acid
EXECUTIVE SUMMARY
INTRODUCTION: Overview of delivery technologies for genetic material: past, present & future; Leading technology platforms for the delivery of genetic material; Nucleic acid delivery: motivators & resistors; Nucleic acid technology motivators; Motivators; Nucleic acid technology resistors; Resistors
ADVANCED NUCLEIC ACID DELIVERY TECHNOLOGIES: Types of nucleic acid-based products under development by the pharma industry; Viral vector delivery of nucleic acids; Schematic of gene therapy utilising HVJ envelope - virosome; Bacterial vector delivery of nucleic acids; Non-viral vector delivery of nucleic acids; Chemical Technologies; Stable nucleic acid-lipid particles; Targeted nanoparticles; Physical Technologies; Schematic of Zosano Pharma’s Patch Technology; Advantages and disadvantages of nucleic acid platforms; Current therapeutic applications for the viral and non-viral delivery of nucleic acids; Leading nucleic acid based products in development; Nucleic acid-based approved/filed drugs; Selection of gene therapies in clinical development; Selection of RNA therapeutics in clinical development; Selection of DNA vaccines in clinical development; Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES: Leading nucleic acid drug delivery companies; Leading nucleic acid drug delivery specialists; Partnerships & acquisitions; Strategic developmental & commercialisation partnerships; Mergers, acquisitions & joint ventures; Recent partnerships & acquisitions in the nucleic acid field; Intellectual Property; Nucleic acid patents; THE vira l and non-vira l vector Delivery MARKET; Now 2009; Approved nucleic acid product sales; Future 2018; Novel nucleic acid product sales; Global controlled release product sales
COMPETITOR ANALYSIS: Movers & Shakers: Cutting edge or losing their grip; Movers & shakers in nucleic acid drug delivery systems
COMPANY PROFILES: Alnylam Pharmaceuticals (www.alnylam.com ); AlphaVax, Inc. (www.alphavax.com); Altea Therapeutics, Inc (www.alteatherapeutics.com); AP Pharma, Inc (www.appharma.com); ArmaGen Technologies (www.armagen.com); BioDelivery Sciences International (www.biodeliverysciences.com); Calando Pharmaceuticals (www.calandopharma.com); Cequent Pharmaceuticals (www.cequentpharma.com); Copernicus Therapeutics (www.cgsys.com); Diatos SA (www.diatos.com); DOR BioPharma, Inc (www.dorbiopharma.com); Expression Genetics, Inc (www.egencorp.com); Inovio Biomedical Corporation (www.inovio.com); MaxCyte, Inc (www.maxcyte.com); Nanotherapeutics (www.nanotherapeutics.com); NeoPharm (www.neopharm.com); Novagali Pharma SA (www.novagali.com); Oxford Biomedica (www.oxfordbiomedica.com); PCI Biotech (www.pcibiotech.com); Silence Therapeutics plc (www.silence-therapeutics.com); Targeted Genetics Corporation (www.targetedgenetics.com); Tekmira Pharmaceuticals Corporation (www.tekmirapharm.com); TissueGene, Inc (www.tissuegene.com); Vical, Inc. (www.vical.com); Zosano Pharma, Inc (www.zosanopharma.com )
APPENDIX 1: Global nucleic acid approved drugs sales 2008-2018
APPENDIX 2: Global nucleic acid developmental drugs sales 2008-2018
APPENDIX 3: Competitor Ratio Analysis Criteria; Key Nucleic acid delivery companies by 2018
GLOSSARY
ACRONYMS
Endnotes: Drug Delivery Technologies: Tar geted
EXECUTIVE SUMMARY
INTRODUCTION: Overview of delivery technologies for targeted delivery: past, present & future; Leading technology platforms for systemic targeted drug delivery; Systemic targeted delivery: motivators & resistors; Motivators; Systemic targeted delivery technology motivators; Resistors; Systemic targeted delivery technology resistors
TARGETED DELIVERY TECHNOLOGIES: Types of systemic targeted delivery platform in development in the pharma industry; Targeting ligands; Antibody fragment conjugate delivery; Antibody-directed enzyme pro-drug targeted delivery; Peptide-induced release for targeted delivery; Small molecule conjugate delivery; Nucleomic mediated targeted intranuclear delivery; Cobalamin mediated targeted intracellular delivery; Non-biological targeting platforms; Magnetically targeted delivery; Photosensitive targeted delivery; Current therapeutic applications for systemic targeted delivery; Leading systemic targeted products in development; Approved systemic and targeted drugs; Future commercial applications & opportunities
STRATEGIES OF DRUG DELIVERY COMPANIES: Leading targeted drug delivery companies; Leading systemic targeted delivery specialists; Partnerships & acquisitions; Strategic alliances; Strategic acquisitions; Recent market activity in targeted delivery companies; Intellectual Property; Targeted drug delivery patents
THE TARGETED DELIVERY MARKET: Now 2009; Approved targeted delivery product sales; Future 2018; Global targeted-release product sales; Novel targeted delivery product sales
COMPETITOR ANALYSIS: Movers & Shakers: Cutting edge or losing their grip; Movers & shakers in targeted drug delivery systems; Abraxis Biosciences (www.abraxisbio.com); Access Pharmaceuticals (www.accesspharma.com); ALZA Corporation (www.alza.com); ArmaGen Technologies (www.armagen.com); Avidimer Therapeutics (www.avidimer.com); Calando Pharmaceuticals (www.calandopharma.com); Cell Therapeutics (www.ctiseattle.com); Cerulean Pharma Inc (www.ceruleanrx.com); Copernicus Therapeutics (www.cgsys.com); CytImmune Sciences Inc (www.cytimmune.com); Diatos SA (www.diatos.com); Enzon Pharmaceuticals, Inc. (www.enzon.com); Endocyte Inc. (www.endocyte.com); Eurand (www.eurand.com); ImmunoGen (www.immunogen.com); ImaRx Therapeutics (www.imarx.com); NanoBioMagnetics, Inc (www.nanobmi.com); Nanobiotix (www.nanobiotix.com); NanoCarrier (www.nanocarrier.co.jp); Nano Interface Technology (www.nanointerfacetech.com); Nektar Therapeutics (www.nektar.com); NeoPharm (www.neopharm.com); Novosom AG (www.novosom.com); PCI Biotech Holding ASA (www.pcibiotech.com); Quest PharmaTech (www.questpharmatech.com); Seattle Genetics (www.seattlegenetics.com); Spherics, Inc (www.spherics.com); Starpharma (www.starpharma.com); Supratek Pharma Inc. (www.supratek.com); Tekmira Pharmaceuticals Corporation (www.tekmirapharm.com)
APPENDIX 1: Global targeted approved drugs sales 2008-2018 (US$ millions)
APPENDIX 2: Global targeted developmental drugs sales 2008-2018 (US$ millions)
APPENDIX 3: Competitor Ratio Analysis Criteria; Key targeted delivery companies by 2018
GLOSSARY
ACRONYMS
BIBLIOGRAPHY
Endnotes

Abstract

Providing...
Critical analyses and competitive ratings for major specialist developers
Unique sales forecasts to 2018 for key current and new products utilising drug delivery technologies
A comprehensive examination of the 4 major and compelling drug delivery sectors

While pharmaceutical sales have risen steadily over the last five years generating over US$720 billion in 2008, analysts are forecasting sales growth will slow over the next five years due to an unprecedented level of patent expiration compounded by the downturn in the global economy. At the same time, the global drug delivery market has undergone rapid growth from an estimated US$26 billion in 2000 to approximately US$74 billion in 2008.

This market has been driven by a number of factors:

Advances in new delivery technology (microencapsulation, nanotechnology);
Development and cost-effective manufacture of new delivery materials (dendrimers, lipid formulations and biodegradable polymers);
Emergence of new delivery specialists expanding the availability of delivery platforms e.g. siRNA delivery;
Patent expiration of leading brands forcing the pharmaceutical industry to evaluate ways to maximise product lifecycles through new formulations, combinations and repositioning;
Renewed interest in the development of novel biologics and vaccines requiring specialised delivery technologies;
Dramatic growth reflected in the evolution of an array of delivery vehicles and hybrid platforms that are increasingly being used to deliver approved and novel therapeutic agents.

Within this market there are areas of advanced drug delivery which have attracted the attention of the pharmaceutical industry and the investment community.
Focusing on the sectors that are driving growth!

VOLUME I
CONTROLLED- RELEASE
VOLUME II
NANOTECHNOLOGY
VOLUME III
NUCLEIC ACID DELIVERY
VOLUME IV
TARGETED DELIVERY

Few sectors of the pharmaceutical industry will be as resistant to the global economic downturn

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Drug Delivery Technologies: Players, Products & Prospects to 2018

Table of Contents

Abstract